Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Research Report 2021

An angiotensin-converting-enzyme inhibitor (ACE inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.

The global Angiotensin Converting Enzyme (ACE) Inhibitors market was valued at US$ XX million in 2020 and is expected to reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.
This report focuses on Angiotensin Converting Enzyme (ACE) Inhibitors volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Angiotensin Converting Enzyme (ACE) Inhibitors market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Sulfhydryl-containing Agents
Dicarboxylate-containing Agents
Phosphonate-containing Agents

Segment by Application
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Abbott Laboratories
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical